


## AN UNSUCCESSFUL APPROACH TO THE FRAMEWORK OF THE ANTIMALARIAL, ARTEETHER

Falmai Binns and Timothy W. Wallace\*


Department of Chemistry and Applied Chemistry,  
University of Salford, Salford M5 4WT, U.K.

**Summary:** The hexahydrobenzopyran **7a**, prepared using the new acetone anion equivalent **17**, reacted with singlet oxygen to produce mixtures containing the dioxetane **6**, but *in situ* treatment with acid failed to generate detectable amounts of **4**, an analogue of the antimalarial arteether **3**.


Although the use of the Chinese herb 'Qinghao' (*Artemisia annua* L.) for the treatment of malaria was first recorded over 1600 years ago,<sup>1</sup> it was not until 1972 that the active principle of this plant was isolated and identified as (+)-artemisinin **1**,<sup>2,3</sup> a sesquiterpene of the cadalane (amorphane) type. The antimalarial activity of this unusual compound, especially against the *Plasmodium falciparum* strains responsible for the most severe forms of the disease, provided a major lead in an area where resistance to existing drug treatments is increasing alarmingly. Extensive studies in China revealed that derivatives of dihydroartemisinin **2** were considerably more potent than the parent compound **1**,<sup>4</sup> and following a research programme coordinated by the World Health Organisation, the ethyl acetal **3**, known as  $\beta$ -arteether, was selected for clinical development as an antimalarial.<sup>5</sup>



**1**




**2**



**3** R = Me

**4** R = H

The novel structure, activity, and low natural yield of artemisinin **1** have prompted three total syntheses,<sup>6-8</sup> an attempted semi-synthesis,<sup>9</sup> the preparation of an analogue,<sup>10</sup> and model studies aimed at securing routes to the biologically crucial 1,2,4-trioxane component of the molecule.<sup>11,12</sup> Our own efforts have been directed towards  $\beta$ -arteether **3**, currently available only *via* artemisinin **1**, and we describe here an attempt to generate the tetracyclic skeleton of **3** directly as the 6,9-bis(demethyl) homologue **4**. Disconnection of the BC portion of **4** reveals that a zwitterionic peroxide **5**, set up for intramolecular capture by the pendant carbonyl group, could function as its immediate precursor (Scheme 1). We therefore sought to prepare the dioxetane **6**, which might give **5** [or an equivalent] directly or under the influence of acid, *via* singlet oxygenation of the bicyclic acetal **7**.




Scheme 1


The approach used to prepare the acetal **7** is summarised in Scheme 2.<sup>13</sup> Heterodiene cycloaddition of ethoxyethene to 2-formylcyclohex-2-en-1-one **8**<sup>14</sup> gave the *exo* and *endo*-cycloadducts **9a** and **9b** (ratio 1:6) in 91% yield, and the kinetic product **9b** was converted into the thermodynamically more stable isomer **9a** by equilibration with acid. Methylenation of **9a** using Lombardo's reagent<sup>15</sup> gave the unstable diene **10**, which on hydroboration gave the hydroxymethyl compound **11** stereospecifically. The structure of **11** was deduced from the high field <sup>1</sup>H n.m.r. spectrum of the derived mesylate **12**, which indicated that two of the three vicinal coupling constants associated with the axial H-7 were large (13 Hz) and that H-8 must therefore be axial.

The forcing conditions needed to effect the displacement of the hindered mesylate **12** with iodide ion caused some epimerisation, yielding a mixture of **13a** and **13b** (ca. 4:1) and serving as a warning that the introduction of the remainder of the side chain would require the use of a particularly reactive acetone anion equivalent. And so it proved. Treatment of **13** with the lithiated acetone hydrazone **14**<sup>16</sup> elicited no reaction at all, while use of the cuprates **15**<sup>17</sup> and **16**<sup>18</sup> gave only traces of the desired product. A reagent with a higher operating temperature was required and, exploiting the principles established by Lipshutz,<sup>19</sup> we prepared the higher order cyanocuprate **17**, which proved stable over an extended period at around 0 °C. Treatment of **17** with the mixture of iodides **13** and unmasking of the carbonyl group using copper(II) chloride<sup>20</sup> thus afforded a workable yield of **7a**.

Photo-oxygenation (Methylene Blue sensitiser) of the ketone **7a** was slow in methanol at -78 °C, conditions known to favour the formation of dioxetanes from enol ethers,<sup>12,21</sup> but was conveniently rapid in CD<sub>3</sub>OD, in which the lifetime of singlet oxygen is enhanced.<sup>22</sup> The starting material gave way to a complex mixture of products whose <sup>1</sup>H n.m.r. spectrum included signals in the region expected for H<sub>A</sub> of the dioxetane **6** (ca. 6 ppm). Treatment of the mixture with acids (formic, Amberlyst® 15) gave new polar products, but the methyl ketone unit from the starting material **7a** was obviously intact ( $\delta > 2.0$ , compared to 1.41 in arteether) both before and after the acid treatment. Evidence that the initial products included the dioxetane **6** was obtained on repeating the reaction in acetonitrile at -40 °C, which gave a mixture from which two of the previously observed products were recovered. The less polar of these was assigned the structure **18** [ $\delta$  8.16 (HCO<sub>2</sub>R), 5.0 (CHOEt)], since it decomposed on standing overnight in CDCl<sub>3</sub> into the more polar **19** [ $\delta$  10.0 (CHO); *m/z* 211 (*M* + 1, 82%), 210 (*M*<sup>+</sup>, 69), 193 (*M* - OH, 100), 180 (*M* - HCHO, 17)], an authentic sample of which is in preparation. The formate **18** is an anticipated<sup>23</sup> thermal scission product of the dioxetane **6**. Treating mixtures presumed to contain the dioxetane **6** with Lewis acids in various solvents gave traces of **18** and **19** as the only recognisable components of complex mixtures. We conclude that photo-oxygenation of the ketone **7a** produces the dioxetane **6**, but that the conversion of the latter into the tetracycle **4** is impracticable from a synthetic point of view.



**Scheme 2** Reagents: i, CH<sub>2</sub>=CHOEt, 20 °C, 3 h (91%); ii, CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, 10 °C, 72 h (75%); iii, CH<sub>2</sub>Br<sub>2</sub>, Zn, TiCl<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C (33 - 43%); iv, 9-BBN, THF, then NaOH, H<sub>2</sub>O<sub>2</sub> (99%); v, MeSO<sub>2</sub>Cl, py (81%); vi, KI, 18-crown-6, THF, reflux, 4 d (69%); vii, **17**, THF, -20 to +10 °C, 72 h, then CuCl<sub>2</sub>, H<sub>2</sub>O, THF, pH 7, 6 h (40%).



This investigation received the financial support of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (project ID No. 840419). We thank Dr. P. Buchs (SAPEC S.A., Lugano, Switzerland) for kindly supplying samples and spectra of arteether, and Dr. C.M. Spencer (University of Sheffield) and the SERC for high field n.m.r. spectra.

## REFERENCES AND NOTES

- 1 Ge Hong in *Zhouhou Bei Ji Fang* (Handbook of Prescriptions for Emergency Treatments), ca. 340 A.D.
- 2 Also known as 'qinghaosu' and 'arteannuin.'
- 3 X-ray structure: Qinghaosu Research Group, *Sci. Sin.*, 1980, **23**, 380 (*Chem. Abs.*, 1980, **93**, 71991).
- 4 For a review, see Xuan-De Luo and Chia-Chiang Shen, *Medicinal Research Reviews*, 1987, **7**, 29.
- 5 A. Brossi, B. Venugopalan, L. Dominguez Gerpe, H.J.C. Yeh, J.L. Flippen-Anderson, P. Buchs, X.D. Luo, W. Milhous, and W. Peters, *J. Med. Chem.*, 1988, **31**, 645.
- 6 G. Schmid and W. Hofheinz, *J. Am. Chem. Soc.*, 1983, **105**, 624.
- 7 X.-X. Xu, J. Zhu, D.-Z. Huang, and W.-S. Zhou, *Tetrahedron*, 1986, **42**, 818.
- 8 M.A. Avery, C. Jennings-White, and W.K.M. Chong, *Tetrahedron Lett.*, 1987, **28**, 4629.
- 9 M. Jung, H.N. ElSohly, E.M. Croom, A.T. McPhail, and D.R. McPhail, *J. Org. Chem.*, 1986, **51**, 5417.
- 10 Y. Imakura, T. Yokoi, T. Yamagishi, J. Koyama, H. Hu, D.R. McPhail, A.T. McPhail, and K.-H. Lee, *J. Chem. Soc., Chem. Commun.*, 1988, 372.
- 11 G. Clark, M. Nikaido, C. Fair, and J. Lin, *J. Org. Chem.*, 1985, **50**, 1994.
- 12 C.W. Jefford, J. Boukouvalas, S. Kohmoto, and G. Bernardinelli, *Tetrahedron*, 1985, **41**, 2081; C.W. Jefford, F. Favarger, S. Ferro, D. Chambaz, A. Bringham, G. Bernardinelli, and J. Boukouvalas, *Helv. Chim. Acta*, 1986, **69**, 1778.
- 13 Yields refer to (racemic) products, isolated by flash chromatography, with satisfactory i.r., <sup>1</sup>H n.m.r., and high resolution m.s. characteristics. Selected n.m.r. data (CDCl<sub>3</sub>): **7a**, (300 MHz) 2.11 (3 H, s, MeCO), 4.85 (1 H, dd, *J* 2.5, 4.4 Hz, 3-H), 5.95 (1 H, br s, 1-H). **7b**, (300 MHz) 4.73 (1 H, dd, *J* 2.0, 8.1 Hz, 3-H), 5.99 (1 H, br s, 1-H). **9a**, (90 MHz) 5.19 (1 H, t, *J* 2 Hz, 3-H), 7.36 (1 H, d, *J* 2 Hz, 1-H). **9b**, (90 MHz) 5.06 (1 H, dd, *J* 2, 10 Hz, 3-H), 7.39 (1 H, d, *J* 2 Hz, 1-H). **10**, (90 MHz) 4.50 (1 H, t, *J* 2 Hz, 3-H), 4.77 (1 H, t, *J* 2.5 Hz, 9-H), 5.06 (1 H, t, *J* 2.5 Hz, 9'-H), 6.44 (1 H, d, *J* 2 Hz, 1-H). **11**, (80 MHz) 4.3 (1 H, br s, 9-H<sub>2</sub>), 4.85 (1 H, m, 3-H), 6.0 (1 H, m, 1-H). **12**, (400 MHz) 1.04 (1 H, ddd, *J* 3.5, 13, 13 Hz, 5<sub>ax</sub>-H), 1.08 (1 H, dddd, *J* 3.5, 13, 13, 13 Hz, 7<sub>ax</sub>-H), 1.215 (3 H, t, *J* 7 Hz, Me), 1.22 (1 H, m, 5<sub>eq</sub>-H), 1.54 (1 H, ddd, *J* 2.5, 9, 13.5 Hz, 4<sub>ax</sub>-H), 2.00 (1 H, ddd, *J* 3.5, 6.5, 13.5 Hz, 4<sub>eq</sub>-H), 2.15 (1 H, m, 4a-H), 2.38 (1 H, m, 8-H), 3.03 (3 H, s, MeSO<sub>2</sub>), 3.45 - 3.6, 3.75 - 3.9 (total 2 H, m, OCH<sub>2</sub>), 4.21 (1 H, dd, *J* 6.5, 9.5 Hz, 9-H), 4.39 (1 H, dd, *J* 5, 9.5 Hz, 9-H), 4.93 (1 H, dd, *J* 2.5, 3.5 Hz, 3-H), 5.97 (1 H, t, *J* 2 Hz, 1-H). **13a**, (80 MHz) 3.0 - 4.0 (4 H, m, OCH<sub>2</sub>, 9-H<sub>2</sub>), 4.85 (1 H, m, 3-H), 6.05 (1 H, m, 1-H); R<sub>f</sub> (CCl<sub>4</sub> - toluene 1:1) 0.38 [**13b**, 0.31].
- 14 D. Liotta, C. Barnum, R. Puleo, G. Zima, C. Bayer, and H.S. Kezar, *J. Org. Chem.*, 1981, **46**, 2920.
- 15 L. Lombardo, *Tetrahedron Lett.*, 1982, **23**, 4293; see also L. Lombardo, *Org. Synth.*, 1987, **65**, 81.
- 16 E.J. Corey and D. Enders, *Tetrahedron Lett.*, 1976, **3**; *idem.*, *Chem. Ber.*, 1978, **111**, 1337.
- 17 E.J. Corey and D.L. Boger, *Tetrahedron Lett.*, 1978, 4597.
- 18 E.J. Corey and D. Enders, *Chem. Ber.*, 1978, **111**, 1362; R.E. Gawley, E.J. Termine, and J. Aube, *Tetrahedron Lett.*, 1980, **21**, 3115.
- 19 B.H. Lipshutz, R.S. Wilhelm, J.A. Kozlowski, and D. Parker, *J. Org. Chem.*, 1984, **49**, 3928; for a review, see B.H. Lipshutz, R.S. Wilhelm, and J.A. Kozlowski, *Tetrahedron*, 1984, **40**, 5005.
- 20 E.J. Corey and S. Knapp, *Tetrahedron Lett.*, 1976, 3667.
- 21 E.W.H. Asveld and R.M. Kellogg, *J. Am. Chem. Soc.*, 1980, **102**, 3644.
- 22 P.B. Merkel and D.R. Kearns, *J. Am. Chem. Soc.*, 1972, **94**, 1029; J.R. Hurst and G.B. Schuster, *ibid.*, 1983, **105**, 5756; M.A.J. Rodgers, *ibid.*, 1983, **105**, 6201.
- 23 See A.A. Frimer, P.D. Bartlett, A.F. Boschung, and J.G. Jewett, *J. Am. Chem. Soc.*, 1977, **99**, 7977.

(Received in UK 16 January 1989)